GlaxoSmithKline plc Company Profile (NYSE:GSK)

About GlaxoSmithKline plc (NYSE:GSK)

GlaxoSmithKline plc logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NYSE:GSK
  • CUSIP: N/A
  • Web:
  • Market Cap: $104 billion
  • Outstanding Shares: 2,443,000,000
Average Prices:
  • 50 Day Moving Avg: $41.93
  • 200 Day Moving Avg: $40.34
  • 52 Week Range: $37.20 - $45.58
  • Trailing P/E Ratio: 48.60
  • Foreward P/E Ratio: 14.88
  • P/E Growth: 1.17
Sales & Book Value:
  • Annual Revenue: $37.31 billion
  • Price / Sales: 2.79
  • Book Value: $0.90 per share
  • Price / Book: 47.30
  • Annual Dividend: $1.83
  • Dividend Yield: 4.6%
  • EBIDTA: $9.37 billion
  • Net Margins: 3.11%
  • Return on Equity: 100.68%
  • Return on Assets: 8.68%
  • Debt-to-Equity Ratio: 2.95%
  • Current Ratio: 0.88%
  • Quick Ratio: 0.61%
  • Average Volume: 2.90 million shs.
  • Beta: 0.94
  • Short Ratio: 2.04

Frequently Asked Questions for GlaxoSmithKline plc (NYSE:GSK)

What is GlaxoSmithKline plc's stock symbol?

GlaxoSmithKline plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline plc pay dividends? What is the dividend yield for GlaxoSmithKline plc?

GlaxoSmithKline plc declared a quarterly dividend on Wednesday, April 26th. Investors of record on Friday, May 12th will be given a dividend of $0.483 per share on Thursday, July 13th. This represents a $1.93 annualized dividend and a yield of 4.54%. The ex-dividend date is Wednesday, May 10th. This is a positive change from GlaxoSmithKline plc's previous quarterly dividend of $0.46. View GlaxoSmithKline plc's Dividend History.

How were GlaxoSmithKline plc's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its earnings results on Wednesday, April, 26th. The company reported $0.62 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $0.62. The firm earned $9.23 billion during the quarter, compared to the consensus estimate of $9.09 billion. GlaxoSmithKline plc had a return on equity of 100.68% and a net margin of 3.11%. View GlaxoSmithKline plc's Earnings History.

Where is GlaxoSmithKline plc's stock going? Where will GlaxoSmithKline plc's stock price be in 2017?

18 analysts have issued 1 year target prices for GlaxoSmithKline plc's shares. Their predictions range from $37.00 to $50.00. On average, they anticipate GlaxoSmithKline plc's share price to reach $45.67 in the next year. View Analyst Ratings for GlaxoSmithKline plc.

Who are some of GlaxoSmithKline plc's key competitors?

Who owns GlaxoSmithKline plc stock?

GlaxoSmithKline plc's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (0.97%), Fisher Asset Management LLC (0.49%), State Street Corp (0.43%), Hotchkis & Wiley Capital Management LLC (0.31%), Bank of America Corp DE (0.28%) and Bank of New York Mellon Corp (0.24%). View Institutional Ownership Trends for GlaxoSmithKline plc.

Who sold GlaxoSmithKline plc stock? Who is selling GlaxoSmithKline plc stock?

GlaxoSmithKline plc's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Hotchkis & Wiley Capital Management LLC, Ameriprise Financial Inc., State Street Corp, Credit Suisse AG, Bank of New York Mellon Corp, BB&T Securities LLC and Jarislowsky Fraser Ltd. View Insider Buying and Selling for GlaxoSmithKline plc.

Who bought GlaxoSmithKline plc stock? Who is buying GlaxoSmithKline plc stock?

GlaxoSmithKline plc's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Thrivent Financial For Lutherans, Renaissance Technologies LLC, Bank of America Corp DE, Global Financial Private Capital LLC, Equity Investment Corp Acquisition Inc, MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. View Insider Buying and Selling for GlaxoSmithKline plc.

How do I buy GlaxoSmithKline plc stock?

Shares of GlaxoSmithKline plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GlaxoSmithKline plc stock cost?

One share of GlaxoSmithKline plc stock can currently be purchased for approximately $42.57.

Analyst Ratings

Consensus Ratings for GlaxoSmithKline plc (NYSE:GSK) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $45.67 (7.27% upside)

Analysts' Ratings History for GlaxoSmithKline plc (NYSE:GSK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/25/2017JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/9/2017Kepler Capital MarketsInitiated CoverageReduce -> ReduceLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageEqual WeightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs Group IncReiterated RatingBuyN/AView Rating Details
11/7/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
10/20/2016InvestecInitiated CoverageBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
9/20/2016Bank of America CorpReiterated RatingBuy$50.00N/AView Rating Details
9/12/2016HSBC Holdings plcReiterated RatingBuyN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
8/12/2016ArgusBoost Price TargetBuy$48.00 -> $50.00N/AView Rating Details
5/26/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00N/AView Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00N/AView Rating Details
11/6/2015Morgan StanleyReiterated RatingNeutralN/AView Rating Details
10/31/2015Societe GeneraleReiterated RatingSellN/AView Rating Details
10/20/2015Credit Suisse Group AGUpgradeUnderperform -> NeutralN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for GlaxoSmithKline plc (NYSE:GSK)
Earnings by Quarter for GlaxoSmithKline plc (NYSE:GSK)
Earnings History by Quarter for GlaxoSmithKline plc (NYSE:GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlaxoSmithKline plc (NYSE:GSK)
2017 EPS Consensus Estimate: $2.89
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.59$0.63$0.61
Q2 20171$0.71$0.71$0.71
Q3 20171$0.83$0.83$0.83
Q4 20171$0.74$0.74$0.74
(Data provided by Zacks Investment Research)


Current Dividend Information for GlaxoSmithKline plc (NYSE:GSK)
Next Dividend:7/13/2017
Annual Dividend:$1.83
Dividend Yield:4.30%
Dividend Growth:-3.10% (3 Year Average)
Payout Ratio:389.36% (Trailing 12 Months of Earnings)
64.66% (Based on This Year's Estimates)
63.99% (Based on Next Year's Estimates)
Dividend Payments by Quarter for GlaxoSmithKline plc (NYSE:GSK)

Dividend History by Quarter for GlaxoSmithKline plc (NYSE:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for GlaxoSmithKline plc (NYSE:GSK)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 8.41%
Insider Trades by Quarter for GlaxoSmithKline plc (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline plc (NYSE:GSK)
Insider Trades by Quarter for GlaxoSmithKline plc (NYSE:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GlaxoSmithKline plc (NYSE:GSK)
Latest Headlines for GlaxoSmithKline plc (NYSE:GSK)
DateHeadline logoGlaxoSmithKline plc (GSK) Given Consensus Recommendation of "Hold" by Analysts - May 23 at 6:04 PM logoGlaxoSmithKline plc (GSK) Stock Rating Upgraded by TheStreet - May 23 at 5:34 PM logoHikma trims FY revenue forecast on Advair U.S. launch delay - May 19 at 9:56 AM logoHikma cuts revenue forecast on generic Advair delay; shares sink - May 19 at 9:56 AM logoU.K. stocks break 2-day losing streak after pound’s mini ‘flash crash’ - May 19 at 9:56 AM logoCiti Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns - May 16 at 5:28 PM logoWest-Ward Columbus sales to take a hit with FDA delay of its generic Advair - May 15 at 5:06 PM logoFrancis Chou Buys Endo International PLC, Teva Pharmaceutical Industries, Valeant ... - May 13 at 9:43 AM logoGlaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration' - May 12 at 6:13 PM logoTop-10 Glaxo investor Woodford sells out, criticises board - May 12 at 6:13 PM logoWhy Big Pharma Is Not at Fault for Record Drug Spending - May 11 at 6:07 PM logoMylan disagrees with FDA over generic Advair delay - May 10 at 5:41 PM logoGlaxo reports positive trial of lung treatment - May 10 at 5:41 PM logoGlaxoSmithKline Plc : GSK-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017 - May 10 at 5:40 PM logoMylan says disagrees with FDA over generic Advair delay - May 10 at 12:02 PM logoGlaxoSmithKline plc (GSK) Given Daily News Impact Rating of 0.16 - May 6 at 12:53 AM logo3 powerful reasons to desire GlaxoSmithKline plc right now - May 5 at 4:07 PM logoGSK And Innoviva Announce Positive Results From SLS In Asthma - May 5 at 4:07 PM logoGlaxoSmithKline plc (GSK) Receiving Somewhat Positive Media Coverage, Study Shows - May 2 at 8:42 PM logoGSK Makes Bullish Cross Above Critical Moving Average - May 2 at 5:42 PM logoAnalyzing GlaxoSmithKline’s Global Pharmaceutical Performance - May 2 at 5:42 PM logoHow GlaxoSmithKline’s Consumer Healthcare Segment Fared in 1Q17 - May 2 at 5:42 PM logoETFs with exposure to GlaxoSmithKline Plc : May 1, 2017 - May 1 at 5:16 PM logoGlaxoSmithKline announces $139 million investment in Rockville - May 1 at 12:50 PM logoIs This Big Pharma Stock's Sky-High Dividend Yield Sustainable? - May 1 at 12:50 PM logoHow Did GlaxoSmithKline’s HIV Business Perform in 1Q17? - May 1 at 12:50 PM logoTriad college awarded $25,000 STEM grant - May 1 at 12:50 PM logoGlaxoSmithKline making $139M investment in Rockville plant - May 1 at 12:50 PM logoGlaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View - Yahoo Finance - April 29 at 6:07 PM logoGlaxoSmithKline plc (GSK) Given Media Impact Score of 0.23 - April 29 at 1:43 PM logoGlaxoSmithKline plc (GSK) Given Consensus Recommendation of "Buy" by Analysts - April 28 at 10:52 PM logoGlaxoSmithKline’s 1Q17 Earnings Surpass Analysts’ Estimates - April 28 at 8:33 PM logoGlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 - April 28 at 3:32 PM logoGlaxoSmithKline plc (GSK) Issues Quarterly Earnings Results, Meets Expectations - April 27 at 6:02 PM logoGlaxoSmithKline plc (gsk) Plans Dividend of $0.48 - April 27 at 2:17 PM logoGlaxoSmithKline plc (GSK) Earning Favorable News Coverage, Report Finds - April 26 at 9:26 PM logoGlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place - April 26 at 7:49 PM logoGlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare - April 26 at 7:49 PM logoAnalyst Ratings and Recommendations for GlaxoSmithKline - April 26 at 7:49 PM logoNew Glaxo Boss Emma Walmsley Seeks Sharper R&D Edge - April 26 at 7:49 PM logoGlaxo meets 1Q profit forecasts - April 26 at 10:28 AM logo[$$] GlaxoSmithKline 1Q Results Expected to Get Boost From Weak Pound - April 25 at 5:06 PM logoGlaxoSmithKline plc (GSK) Upgraded to Hold at Zacks Investment Research - April 25 at 3:42 PM logoGlaxoSmithKline plc's (GSK) Neutral Rating Reaffirmed at JPMorgan Chase & Co. - April 25 at 2:35 PM logoThis fast-growing pharmaceutical stock blows GlaxoSmithKline plc out of the water - April 24 at 5:18 PM logoFY2017 EPS Estimates for GlaxoSmithKline plc Lowered by Jefferies Group (GSK) - April 24 at 9:12 AM logoLeerink Swann Analysts Decrease Earnings Estimates for GlaxoSmithKline plc (GSK) - April 24 at 8:04 AM logoGlaxoSmithKline plc (GSK) Earning Favorable Press Coverage, Analysis Finds - April 23 at 6:15 PM logoWhat's in Store for GlaxoSmithKline (GSK) in Q1 Earnings? - April 21 at 5:31 PM logoAnalyst Estimates for Novartis’s 1Q17 Earnings - April 21 at 5:31 PM



GlaxoSmithKline plc (GSK) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff